Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide Nanoparticles (adv. Healthcare Mater. 14/2022)

Theranostics The study in article number 2102816 by Hui Mao and co-workers reports systemic and targeted delivery of sub-5 nm theranostic iron oxide nanoparticles carrying the anti-cancer topoisomerase I inhibitor, SN38, to the intracranial tumors of glioblastoma via the enhanced permeability and retention effect and tumor integrin targeting, leading to improved efficacy of tumor growth inhibition.